Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
773.98-
QQQ
721.640.55%
BTC/USD
81184.600.1126%
DIA
536.670.05%
GLD
410.340.03%
TLT
82.270.24%

Rani Therapeutics Holdings Inc

RANINASDAQ
Trade with Public
Trade with Public
$0.8522
-0.0058-0.68%
At close: Sep 2, 5:00 PM EST
$0.8510
-0.007-0.82%
Pre-Market: 6:12 AM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Rani Therapeutics Hldgs Analyst Price Targets

Wall Street analyst price targets and consensus rating for Rani Therapeutics Hldgs (RANI).

Price Target Range — 12 Quarters

Analyst Consensus — 8 Analysts

8Buy
Consensus RatingBuy# Analysts8Avg. Consensus PT$9Upside to Avg. PT+978.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 21, 2026HC Wainwright & Co.Brandon FolkesMaintainedBuy$11
Aug 18, 2026Chardan CapitalAndreas ArgyridesInitiateBuy$6
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $11 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy and maintains $11 price target.
Benzinga Newsdesk

This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top analysts changed outlook on top names. See analyst ratings page for all changes.
Avi Kapoor

PRO
Chardan Capital Initiates Coverage On Rani Therapeutics Hldgs with Buy Rating, Announces Price Target of $6

Chardan Capital analyst Andreas Argyrides initiates coverage on Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy rating and announces Price Target of $6.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Rani Therapeutics Hldgs, Lowers Price Target to $5

Canaccord Genuity analyst Edward Nash maintains Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy and lowers the price target from $9 to $5.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $11 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy and maintains $11 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $11 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy and maintains $11 price target.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved